317 related articles for article (PubMed ID: 37999111)
1. Unveiling Therapeutic Targets for Esophageal Cancer: A Comprehensive Review.
Acharya R; Mahapatra A; Verma HK; Bhaskar LVKS
Curr Oncol; 2023 Oct; 30(11):9542-9568. PubMed ID: 37999111
[TBL] [Abstract][Full Text] [Related]
2. Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer.
Kadono T; Yamamoto S; Kato K
Jpn J Clin Oncol; 2022 Oct; 52(10):1089-1096. PubMed ID: 36047845
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Blockade and Targeted Therapies in Esophageal Cancer.
Yang J; Janjigian YY
Thorac Surg Clin; 2022 Nov; 32(4):467-478. PubMed ID: 36266034
[TBL] [Abstract][Full Text] [Related]
4. The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction.
Valkema MJ; Mostert B; Lagarde SM; Wijnhoven BPL; van Lanschot JJB
Updates Surg; 2023 Feb; 75(2):313-323. PubMed ID: 35836094
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
Tintelnot J; Goekkurt E; Binder M; Thuss-Patience P; Lorenzen S; Knorrenschild JR; Kretzschmar A; Ettrich T; Lindig U; Jacobasch L; Pink D; Al-Batran SE; Hinke A; Hegewisch-Becker S; Nilsson S; Bokemeyer C; Stein A
BMC Cancer; 2020 Jun; 20(1):503. PubMed ID: 32487035
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab for the treatment of esophageal cancer.
Mikuni H; Yamamoto S; Kato K
Expert Opin Biol Ther; 2021 Jun; 21(6):697-703. PubMed ID: 33736560
[No Abstract] [Full Text] [Related]
7. Current developments in gastric cancer: from molecular profiling to treatment strategy.
Alsina M; Arrazubi V; Diez M; Tabernero J
Nat Rev Gastroenterol Hepatol; 2023 Mar; 20(3):155-170. PubMed ID: 36344677
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial.
Lin Y; Liang HW; Liu Y; Pan XB
Front Immunol; 2023; 14():1264912. PubMed ID: 37860010
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
Shah MA; Kennedy EB; Alarcon-Rozas AE; Alcindor T; Bartley AN; Malowany AB; Bhadkamkar NA; Deighton DC; Janjigian Y; Karippot A; Khan U; King DA; Klute K; Lacy J; Lee JJ; Mehta R; Mukherjee S; Nagarajan A; Park H; Saeed A; Semrad TJ; Shitara K; Smyth E; Uboha NV; Vincelli M; Wainberg Z; Rajdev L
J Clin Oncol; 2023 Mar; 41(7):1470-1491. PubMed ID: 36603169
[TBL] [Abstract][Full Text] [Related]
10. Advances in targeted therapy for esophageal cancer.
Yang YM; Hong P; Xu WW; He QY; Li B
Signal Transduct Target Ther; 2020 Oct; 5(1):229. PubMed ID: 33028804
[TBL] [Abstract][Full Text] [Related]
11. Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma.
Peng C; Cohen DJ
Expert Opin Pharmacother; 2021 Jan; 22(1):93-107. PubMed ID: 33034212
[TBL] [Abstract][Full Text] [Related]
12. [Current status and prognosis of immune checkpoint inhibitors for esophageal cancer].
Gao HJ; Shang XB; Yu ZT
Zhonghua Wai Ke Za Zhi; 2019 Oct; 57(10):77-82. PubMed ID: 31510736
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in esophagogastric cancer.
Ilson DH
Clin Adv Hematol Oncol; 2021 Oct; 19(10):639-647. PubMed ID: 34637430
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and therapeutic molecular markers in the clinical management of esophageal cancer.
Zhou N; Hofstetter WL
Expert Rev Mol Diagn; 2020 Apr; 20(4):401-411. PubMed ID: 32067548
[No Abstract] [Full Text] [Related]
15. Nivolumab with or without chemotherapy for metastatic gastroesophageal cancers and future perspectives.
Sewastjanow-Silva M; Yamashita K; Rosa Vicentini E; Hirschmann M; Pool Pizzi M; Trail AM; Waters RE; Rogers JE; Ajani JA
Expert Rev Anticancer Ther; 2022 Nov; 22(11):1177-1181. PubMed ID: 36266061
[TBL] [Abstract][Full Text] [Related]
16. Tsunami of immunotherapies in the management of esophageal cancer.
Kassab J; Saba L; Kassab R; Kourie HR
Immunotherapy; 2022 Aug; 14(11):879-884. PubMed ID: 35703028
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies for esophageal cancer.
Tew WP; Kelsen DP; Ilson DH
Oncologist; 2005 Sep; 10(8):590-601. PubMed ID: 16177283
[TBL] [Abstract][Full Text] [Related]
18. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
Moehler M; Högner A; Wagner AD; Obermannova R; Alsina M; Thuss-Patience P; van Laarhoven H; Smyth E
Eur J Cancer; 2022 Nov; 176():13-29. PubMed ID: 36183651
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab for esophageal cancer: an updated meta-analysis of randomized controlled trials.
Huang ZH; Ma XW; Zhang J; Li X; Lai NL; Zhang SX
BMC Cancer; 2018 Nov; 18(1):1170. PubMed ID: 30477458
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in Gastric Cancer.
Högner A; Moehler M
Curr Oncol; 2022 Mar; 29(3):1559-1574. PubMed ID: 35323331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
